Brean Murray Initiates Coverage on Obagi Medical Products (OMPI) with Buy
More News related to OMPI
- Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
- OBAGI Medical (OMPI) Posts Q3 EPS of $0.14, In-Line with Street; Guides
- Obagi Medical Products Reports Third Quarter 2009 Earnings
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009
Brean Murray initiates coverage on Obagi Medical Products (Nasdaq: OMPI) with Buy. Price target $10
Brean analyst says, "The stock, along with the perception of the company's near-term prospects, has been battered by the economic downturn. Nevertheless, we believe that the company's market-leading brand and customer base, its products' synergies with other aesthetic products like Botox and laser therapy, and its potential as an acquisition, make the risk/reward proposition compelling at these levels."
Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets.
Related Categories
New CoverageStocks Mentioned
+0.64Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
